Vejmola, Čestmír http://orcid.org/0000-0002-6434-5978
Tylš, Filip http://orcid.org/0000-0002-8337-6999
Piorecká, Václava
Koudelka, Vlastimil
Kadeřábek, Lukáš
Novák, Tomáš http://orcid.org/0000-0001-9156-9654
Páleníček, Tomáš http://orcid.org/0000-0002-3109-9539
Funding for this research was provided by:
Grantová Agentura, Univerzita Karlova (1780218)
Ministerstvo Vnitra České Republiky (VI20172020056, VI20172020056, VI20172020056, VI20172020056, VI20172020056)
Ministerstvo Zdravotnictví Ceské Republiky (00023752, 00023752, 00023752, 00023752, 00023752)
Ministerstvo Školství, Mládeže a Tělovýchovy (LO1611, LO1611, LO1611, LO1611, LO1611)
Grantová Agentura České Republiky (18-16218, 20-25349S, 18-16218, 18-16218)
Article History
Received: 2 July 2021
Revised: 16 July 2021
Accepted: 18 August 2021
First Online: 2 October 2021
Competing interests
: Dr. TP and FT declare to have shares in “Psychedelická klinika s.r.o” and are involved in Compass Pathways trials with psilocybin and MAPS clinical trial with MDMA outside the submitted work. Dr. TP has founded “PSYRES - Psychedelic Research Foundation”, has shares in “Společnost pro podporu neurovědního výzkumu s.r.o” and reports consulting fees from GH Research and CB21-Pharma outside the submitted work. Dr. FT is the head of PSYRES scientific committee. The remaining authors declare no potential conflict of interest with regard to this study.